KRAS and non-small cell lung carcinoma: In-human trials were planned in KRAS G12D mutant NSCLC based on preclinical data showing cellular models relying on the nuclear factor-kappa B (NF-κB) pathway and cellular death induced by inhibition of NF-κB.